Envista Holdings Corporation Common Stock (NY:NVST)

23.46 +0.30 (+1.30%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Envista Holdings Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Solventum, Envista, ICU Medical, Globus Medical, and Enovis Stocks Trade Up, What You Need To Know

May 12, 2025

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...

Via StockStory

Envista (NYSE:NVST) Surprises With Q1 Sales

May 01, 2025

Dental products company Envista Holdings (NYSE:NVST) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.1% year on year to $616.9 million. Its non-GAAP profit of $0.24 per share...

Via StockStory

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Envista (NVST) To Report Earnings Tomorrow: Here Is What To Expect

April 30, 2025

Dental products company Envista Holdings (NYSE:NVST) will be announcing earnings results tomorrow after market close. Here’s what investors should know.

Via StockStory

Envista Holdings Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗

February 25, 2025

Via Benzinga

Envista Holdings Earnings Review: Q4 Summary ↗

February 05, 2025

Via Benzinga

Insights into Envista Holdings Q4 Earnings ↗

February 05, 2025

Via Benzinga

7 Analysts Have This To Say About Envista Holdings ↗

April 29, 2025

Via Benzinga

Q4 Rundown: Dentsply Sirona (NASDAQ:XRAY) Vs Other Dental Equipment & Technology Stocks

April 28, 2025

Let’s dig into the relative performance of Dentsply Sirona (NASDAQ:XRAY) and its peers as we unravel the now-completed Q4 dental equipment & technology earnings season.

Via StockStory

Envista (NVST): Buy, Sell, or Hold Post Q4 Earnings?

April 24, 2025

Over the last six months, Envista shares have sunk to $15.51, producing a disappointing 18.5% loss - worse than the S&P 500’s 8.1% drop. This was partly driven by its softer quarterly results and might...

Via StockStory

Topics Stocks

3 Cash-Producing Stocks with Questionable Fundamentals

April 21, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Earnings Scheduled For February 5, 2025 ↗

February 05, 2025

Via Benzinga

5 Analysts Have This To Say About Envista Holdings ↗

January 23, 2025

Via Benzinga

Demystifying Envista Holdings: Insights From 7 Analyst Reviews ↗

December 04, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Envista Holdings ↗

October 23, 2024

Via Benzinga

Q4 Earnings Highs And Lows: Envista (NYSE:NVST) Vs The Rest Of The Dental Equipment & Technology Stocks

April 16, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Envista (NYSE:NVST) and the best and worst...

Via StockStory

Dental Equipment & Technology Stocks Q4 Earnings Review: Align Technology (NASDAQ:ALGN) Shines

March 10, 2025

Let’s dig into the relative performance of Align Technology (NASDAQ:ALGN) and its peers as we unravel the now-completed Q4 dental equipment & technology earnings season.

Via StockStory

Dental Equipment & Technology Stocks Q4 In Review: Henry Schein (NASDAQ:HSIC) Vs Peers

March 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Henry Schein (NASDAQ:HSIC) and the best and...

Via StockStory

Earnings To Watch: Dentsply Sirona (XRAY) Reports Q4 Results Tomorrow

February 26, 2025

Dental products company Dentsply Sirona (NASDAQ:XRAY) will be announcing earnings results tomorrow morning. Here’s what you need to know.

Via StockStory

Kerr Introduces SimpliShade Self-Adhesive Flow

October 07, 2024

Via ACCESSWIRE

Henry Schein (HSIC) Q4 Earnings Report Preview: What To Look For

February 24, 2025

Dental and Medical products company Henry Schein (NASDAQ:HSIC) will be reporting results tomorrow morning. Here’s what investors should know.

Via StockStory

DEXIS Showcases Newest Technology at Chicago Midwinter and Lab Day Conferences

February 19, 2025

Via ACCESS Newswire

Edwards Lifesciences (EW) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 10, 2025

Medical technology company Edwards Lifesciences (NYSE:EW) will be reporting results tomorrow after market close. Here’s what to look for.

Via StockStory

Envista’s (NYSE:NVST) Q4 Sales Beat Estimates

February 05, 2025

Dental products company Envista Holdings (NYSE:NVST) announced better-than-expected revenue in Q4 CY2024, with sales up 1.1% year on year to $652.9 million. Its non-GAAP profit of $0.24 per share was...

Via StockStory

Topics Earnings

What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players? ↗

December 12, 2024

Patient Square Capital agrees to buy Patterson Companies for $4.1 billion. Analysts predict minimal regulatory hurdles and a strong bid unlikely to face competition.

Via Benzinga

This Wingstop Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

October 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 30, 2024

Via Benzinga

Kerr Dental Releases ZenFlex CM Rotary File for Predictable and Effective Endodontic Procedures

October 23, 2024

Via ACCESSWIRE

DEXIS Expands Digital Ecosystem With Three New Innovations To Connect and Streamline Dental Workflows

September 24, 2024

Via ACCESSWIRE

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.